Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C.[2] It is specifically used for hepatitis C genotype 1 and 4.[2] Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa.[2] Cure rates are in 80s to 90s percent.[3][4][5] It may be used in those who also have HIV/AIDS.[2] It is taken by mouth once daily for typically 12 weeks.[2]
Common side effects include feeling tired, headache, rash, itchiness, and sensitivity to sunlight.[2] In those with previous hepatitis B infection, active disease may recur.[2] It is not recommended in those with significant liver problems.[2] During pregnancy when used with ribavirin it may cause harm to the baby while when used with sofosbuvir its safety is unclear.[2][6] Simeprevir is a HCV protease inhibitor.[2]
Simeprevir was developed by Medivir AB and Janssen Pharmaceutica.[7] It was approved for medical use in the United States in 2013.[8] It was removed from the World Health Organization's List of Essential Medicines in 2019.[9][10] It is not available as a generic medication as of 2015[update].[6]
^"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ abcdefghij"Simeprevir". The American Society of Health-System Pharmacists. Archived from the original on 1 December 2016. Retrieved 30 November 2016.
^"Initial treatment of HCV infection". www.hcvguidelines.org. October 2016. Archived from the original on 7 December 2016. Retrieved 1 December 2016.
^Majumdar A, Kitson MT, Roberts SK (June 2016). "Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis". Alimentary Pharmacology & Therapeutics. 43 (12): 1276–92. doi:10.1111/apt.13633. PMID 27087015.
^Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G (April 2015). "Which therapeutic option for hepatitis C virus genotype 1?". Scandinavian Journal of Gastroenterology. 50 (4): 470–8. doi:10.3109/00365521.2014.978364. PMID 25396710. S2CID 34382861.
^ abHamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 80. ISBN 9781284057560.
^Grubbs RH, O'Leary DJ (2015). Handbook of Metathesis, Volume 2: Applications in Organic Synthesis. John Wiley & Sons. p. 699. ISBN 9783527694020.
^Dugum M, O'Shea R (March 2014). "Hepatitis C virus: here comes all-oral treatment". Cleveland Clinic Journal of Medicine. 81 (3): 159–72. doi:10.3949/ccjm.81a.13155. PMID 24591471. S2CID 37838853.
^World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
^World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
Simeprevir, sold under the brand name Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C...
than 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that proved...
been previously infected. In combination with ledipasvir, daclatasvir or simeprevir, it is not recommended with amiodarone due to the risk of an abnormally...
including atazanavir (when taken with ritonavir), lopinavir/ritonavir and simeprevir Alcohol intake should be reduced while on rosuvastatin in order to decrease...
On November 22, the FDA approved simeprevir for use in combination with peginterferon-alfa and ribavirin. Simeprevir has been approved in Japan for the...
classes: NS3 and NS4A protease inhibitors, including telaprevir, boceprevir, simeprevir, and others NS5A inhibitors, including ledipasvir, daclatasvir, and others...
hepatitis C, it is used in combination with other medications such as simeprevir, sofosbuvir, peginterferon alfa-2b or peginterferon alfa-2a. Among the...
none Blood testing for antibodies or viral RNA Antivirals (sofosbuvir, simeprevir, others) Under research Hepatitis D Virus Hepatitis D Feeling tired, nausea...
channel antagonist Ritonavir HIV HIV-1 protease inhibitor Saquinavir HIV Simeprevir (Olysio) Hepatitis C Sofosbuvir Hepatitis C nucleoside analogue reverse...
produced lymphoma remissions in <50% of cases. More recently, drugs (e.g. simeprevir, daclatasvir, sofosbuvir, and dasabuvir) that directly inhibit the virus's...
Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway. Discovery and development of NS5A inhibitors Vince...
anti-tuberculosis drug Rilpivirine (TMC278, tradename Edurant), an NNRTI Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment...
boceprevir was approved. Thereafter other inhibitors in this class telaprevir, simeprevir, asunaprevir, paritaprevir and grazoprevir were approved. 2013 – The first...
ciluprevir scaffold was exploited to design new macrocyclic inhibitors such as simeprevir (TMC-435) and danoprevir. Tan SL, He Y, eds. (2011). Hepatitis C: Antiviral...
years. Esmat succeeded in the offering of variable DAAs (as sofosbuvir, simeprevir, daclatasvir, ombitasvir and paritaprevir, ledipasvir) in Egypt at affordable...
Global Information
